GM closes out the week with the contradiction that defined the prior note still unresolved — options traders have dialled back their bullishness while the analyst community remains broadly constructive, leaving the stock caught between two competing reads on the same underlying business.
The options shift is worth noting. The put/call ratio has edged up to 0.66, still below the 20-day mean of 0.68 but no longer the extreme call-heavy reading that stood out last week. The z-score has pulled back to -1.3 from the near-three-standard-deviation trough visible on August 26. That suggests some of the aggressive upside positioning has unwound, though the PCR remains well below its 52-week high of 1.10 — options traders are less euphoric but not yet defensive. Short interest tells an equally quiet story: at 2.2% of the free float, bears haven't materially re-entered, and the borrow market remains essentially unlimited with availability at the cap and cost to borrow a negligible 0.35%. Short interest did tick up about 5% on the week, reversing part of the sharp 23% month-on-month decline, but nothing in the lending market suggests conviction on the short side.
The Street remains the clearest bullish anchor. Following GM's strong Q2 print on July 21 — when the stock jumped 8.4% on the day and extended to nearly 19% over the following five sessions — a wave of analysts lifted targets. JPMorgan raised its target to $120, Goldman Sachs moved to $103, and Barclays to $110, all maintaining positive ratings. Jefferies went further, upgrading from Hold to Buy with a $99 target. The sole dissenter is Wells Fargo, holding an Underweight with a $61 target — a notable outlier against a consensus mean of $101.58. That consensus implies roughly 19% upside from the current $85.63. Valuation remains undemanding: the stock trades at a forward P/E of just 6.0x and an EV/EBITDA of 7.8x, both little changed over the past 30 days. The analyst differentiation factor score ranks in the 96th percentile — meaning GM's rating dispersal is unusually wide, which itself captures the bull-bear divide neatly.
The insider picture remains a constraint on pure bullish conviction, though it has gone quiet since the previous note. The most recent open-market activity on record was EVP Grant Michael Dixton's planned sale of 40,000 shares at $88.44 on August 3 — a $3.5 million disposal under a pre-arranged 10b5-1 plan. The 10b5-1 designation matters: this was a scheduled sale, not a discretionary signal. No open-market purchases appear in the 90-day window. On the institutional register, Capital Research added roughly 800,000 shares and FMR added nearly 2.8 million through July — both modest signals of incremental demand from active managers. BlackRock's most recent Schedule 13G/A, filed in April 2025, showed a reduction from 9.0% to 7.5%, though the current institutional data shows them holding 8.81% — a reminder that 13D/G disclosures are event-driven snapshots around the 5% threshold, and positions can shift materially between filings.
Relative to close peers, GM's week was comparatively contained. F fell 0.8% on the week, largely in step. European peers fared differently: BMW gained 5.5% and STLAM added 3.5%, suggesting some rotation into European auto names that GM did not share. WGO and THO — lower-correlation peers — dropped 8% and 6.4% respectively, underperforming sharply.
With next earnings confirmed for October 20, the focus over the coming weeks is whether the gap between the stock at $85.63 and the consensus target above $100 begins to close — or whether the Wells Fargo $61 bear case finds more company as the macro backdrop for auto demand becomes clearer.
See the live data behind this article on ORTEX.
Open GM on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
